David Shaw’s MoonLake Immunotherapeutics MLTX Stock Holding History

David Shaw’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$65.5M	Buy	3,365,507 +974,846	+41%	+$17.7M	0.03%	626
2026 Q1	$44.6M	Sell	2,390,661 -90,106	-4%	-$1.49M	0.03%	710
2025 Q4	$32.7M	Buy	+2,480,767	New	+$29.3M	0.02%	943
2024 Q1	–	Sell	-128,700	Closed	-$7.77M	–	4586
2023 Q4	$7.77M	Buy	+128,700	New	+$6.63M	0.01%	1569
2022 Q2	–	Sell	-337,021	Closed	-$3.74M	–	5595
2022 Q1	$3.74M	Hold	337,021	–	–	﹤0.01%	2656
2021 Q4	$3.33M	Buy	337,021 +296,968	+741%	+$2.95M	﹤0.01%	2831
2021 Q3	$395K	Buy	40,053 +17,040	+74%	+$170K	﹤0.01%	4219
2021 Q2	$238K	Buy	+23,013	New	+$234K	﹤0.01%	4391

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

California State Teachers Retirement System (CalSTRS) West Sacramento, California $782B AUM 28.39% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

David Shaw's MLTX Position: Q2 2026 in Review

David Shaw increased its MoonLake Immunotherapeutics (MLTX) stake by 41% in Q2 2026, buying an estimated $17.7M and bringing the position to 3,365,507 shares worth $65.5M. The position accounts for 0.03% of the portfolio, ranked #626.

David Shaw first reported a position in MLTX in Q2 2021 and has held it in 8 quarters since. 172 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

David Shaw held 3,365,507 shares of MoonLake Immunotherapeutics worth $65.5M as of Q2 2026.
David Shaw bought 974,846 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $17.7M.
MoonLake Immunotherapeutics made up 0.03% of David Shaw's portfolio in Q2 2026, its #626 holding.
David Shaw first reported a position in MoonLake Immunotherapeutics in Q2 2021 and has held it in 8 quarters since.
172 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.